Company: Symptify
Overview
Symptify is an innovative online self-assessment tool founded in 2013, aimed at empowering individuals to make informed health decisions through a customized algorithmic engine. By merging the expertise of emergency room physicians with advanced software engineering, Symptify offers a pragmatic approach to healthcare. It is headquartered at 18101 Collins Ave PH#306, Sunny Isles Beach, Florida 33160-3470, US, and is a part of the IT Services and IT Consulting industry.
Products and Services
Symptify's main product is a mobile application serving as a "virtual doctor," which enables users to conveniently assess their symptoms. The app aids in identifying potential causes of symptoms, suggests the appropriate level of care, and helps locate nearby healthcare services. This not only enhances healthcare accessibility but also contributes to reducing unnecessary medical costs by providing preliminary assessments.
Team and Leadership
- Jalil Thurber: Founder and CEO, leveraging over 11 years of experience as an emergency physician. Thurber spearheads Symptify's strategic direction and technological evolution, recognized for harnessing technology to improve patient outcomes.
- Franc Nemanic: Experienced CEO, board member, and angel investor. As an investor associated with Symptify, Nemanic provides critical business acumen and industry connections essential for the company's expansion and market presence.
Company Information
- Type: Public Company
- Founded: 2013
- Employees: 2-10
Fundraising and Financials
Symptify secured USD 250,000 during its initial seed round on August 12, 2013. This funding played a crucial role in the development and scaling of its proprietary technology to reach and meet market demand effectively.
Market and Industry Context
Symptify operates at the intersection of healthcare and technology, focusing on medical information technology, health solutions, medical advertising, and medical education. The company's mission emphasizes simplifying the process of symptom evaluation and directing users to suitable healthcare interventions, mirroring the broader industry shift towards consumer empowerment in healthcare decisions.
Competitor Profiling
Key Competitors
Symptify faces competition from several companies in the digital health solutions sphere:
1. ThinkAndor® by Andor Health
- Overview: Founded in 2018 and headquartered in Orlando, Florida, ThinkAndor® is an AI-driven virtual care collaboration platform by Andor Health. It aims to enhance care delivery with real-time actionable intelligence.
- Achievements: Achieved notable reductions in patient management metrics, serving over 500 hospitals and 70,000 providers globally.
2. Virtual Triage & Care Navigation by Clearstep
- Overview: Based in Chicago and founded in 2018, Clearstep provides AI-powered healthcare services that aid patient autonomy and streamline navigation.
- Key Feature: Sole provider of Schmitt Clinical Content for accurate chat-based digital self-triage.
3. Ada Health
- Overview: With headquarters in Berlin, Germany, Ada Health leads in symptom assessment applications, delivering AI-driven health navigation.
- Impact: Boasts 13 million users and over 32 million assessments completed.
4. Mediktor
- Overview: Founded in Spain in 2011, Mediktor offers AI-based medical assistance for triage and pre-diagnosis.
- Financials: Profits around $15 million annually and collaborates with global health organizations.
5. Orbita
- Overview: Incorporates conversational AI for enhanced patient engagement across healthcare systems.
- Unique Selling Point: Integrates smart virtual assistants meeting privacy standards to improve health service operations.
Strategic Insights
Symptify distinguishes itself by uniting ER physician expertise with advanced software techniques, offering a unique self-assessment tool. Competitors largely optimize through AI excellence, integration, and scalable healthcare solutions. To capitalize on market opportunities, Symptify should accentuate its commitment to user empowerment and educational resources, spotlighting its algorithmic accuracy backed by medical expertise as a competitive edge over broad-spectrum AI solutions.
